Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × TVB-2640 × Clear all
NCT03032484 2023-06-15

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
25 enrolled 9 charts
CNS

Astrocytoma

NCT02223247 2017-08-14

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Sagimet Biosciences Inc.

Phase 1 Completed
180 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡